Menu
Search
|

Menu

Close
X

Chimerix Inc CMRX.OQ (NASDAQ Stock Exchange Global Market)

4.64 USD
+0.03 (+0.65%)
As of 12:04 AM IST
chart
Previous Close 4.61
Open 4.62
Volume 10,225
3m Avg Volume 46,725
Today’s High 4.66
Today’s Low 4.59
52 Week High 5.93
52 Week Low 4.18
Shares Outstanding (mil) 47.05
Market Capitalization (mil) 244.17
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.14 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
4
FY16
6
FY15
11
EPS (USD)
FY18
-0.416
FY17
-1.511
FY16
-1.652
FY15
-2.646
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
55.67
5.73
Price to Book (MRQ)
vs sector
0.98
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-24.14
14.61
Return on Equity (TTM)
vs sector
-24.17
16.34

EXECUTIVE LEADERSHIP

Martha Demski
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Michelle Berrey
President, Chief Executive Officer, Chief Medical Officer, Director, Since 2014
Salary: $419,273.00
Bonus: $294,800.00
Timothy Trost
Chief Financial Officer, Senior Vice President, Corporate Secretary, Since 2012
Salary: $275,000.00
Bonus: $34,375.00
Roy Ware
Chief Manufacturing and Technology Officer, Since 2017
Salary: --
Bonus: --
Heather Knight-Trent
Vice President - Regulatory Affairs, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2505 Meridian Pkwy Ste 100
DURHAM   NC   27713-2288

Phone: +1919.8061074

Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.

SPONSORED STORIES